Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Dna X (SONM) over the last 4 years, with Q3 2025 value amounting to $984927.0.

  • Dna X's Shares Outstanding (Diluted Average) rose 26561.65% to $984927.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $984927.0, marking a year-over-year increase of 26561.65%. This contributed to the annual value of $4.7 million for FY2024, which is 1003.91% up from last year.
  • According to the latest figures from Q3 2025, Dna X's Shares Outstanding (Diluted Average) is $984927.0, which was up 26561.65% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Shares Outstanding (Diluted Average) registered a high of $41.1 million during Q1 2023, and its lowest value of $269388.0 during Q3 2024.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $4.7 million (2024), whereas its average is $12.5 million.
  • In the last 5 years, Dna X's Shares Outstanding (Diluted Average) crashed by 9390.25% in 2024 and then surged by 26561.65% in 2025.
  • Quarter analysis of 4 years shows Dna X's Shares Outstanding (Diluted Average) stood at $28.9 million in 2022, then tumbled by 85.16% to $4.3 million in 2023, then rose by 10.04% to $4.7 million in 2024, then crashed by 79.12% to $984927.0 in 2025.
  • Its Shares Outstanding (Diluted Average) was $984927.0 in Q3 2025, compared to $9.5 million in Q2 2025 and $5.9 million in Q1 2025.